| pubmed-article:17888064 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0078988 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0020538 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0022658 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0011860 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0205147 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0003364 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0051696 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0288171 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0010181 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0439858 | lld:lifeskim |
| pubmed-article:17888064 | lifeskim:mentions | umls-concept:C0205087 | lld:lifeskim |
| pubmed-article:17888064 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:17888064 | pubmed:dateCreated | 2008-5-20 | lld:pubmed |
| pubmed-article:17888064 | pubmed:abstractText | The prevalence of type 2 diabetes, often leading to diabetic nephropathy, has increased globally, especially in Asia. Irbesartan treatment delays the progression of kidney disease at the early (microalbuminuria) and late (proteinuria) stages of nephropathy in hypertensive type 2 diabetics. This treatment has proven to be cost-effective in Western countries. This study assessed the cost-effectiveness of early irbesartan treatment in Asian settings. | lld:pubmed |
| pubmed-article:17888064 | pubmed:language | eng | lld:pubmed |
| pubmed-article:17888064 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17888064 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:17888064 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17888064 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17888064 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17888064 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17888064 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:17888064 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:17888064 | pubmed:issn | 1524-4733 | lld:pubmed |
| pubmed-article:17888064 | pubmed:author | pubmed-author:YangWu-ChangW... | lld:pubmed |
| pubmed-article:17888064 | pubmed:author | pubmed-author:AnnemansLieve... | lld:pubmed |
| pubmed-article:17888064 | pubmed:author | pubmed-author:PalmerAndrew... | lld:pubmed |
| pubmed-article:17888064 | pubmed:author | pubmed-author:LeeTae-JinTJ | lld:pubmed |
| pubmed-article:17888064 | pubmed:author | pubmed-author:SupapornThano... | lld:pubmed |
| pubmed-article:17888064 | pubmed:author | pubmed-author:DemarteauNadi... | lld:pubmed |
| pubmed-article:17888064 | pubmed:author | pubmed-author:HuShanlianS | lld:pubmed |
| pubmed-article:17888064 | pubmed:author | pubmed-author:MoradZaherZ | lld:pubmed |
| pubmed-article:17888064 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:17888064 | pubmed:volume | 11 | lld:pubmed |
| pubmed-article:17888064 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:17888064 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:17888064 | pubmed:pagination | 354-64 | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:meshHeading | pubmed-meshheading:17888064... | lld:pubmed |
| pubmed-article:17888064 | pubmed:articleTitle | An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy. | lld:pubmed |
| pubmed-article:17888064 | pubmed:affiliation | Ghent University and IMS Health, Bruxelles, Belgium, and IMS Health, Bruxelles, Belgium. | lld:pubmed |
| pubmed-article:17888064 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:17888064 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:17888064 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:17888064 | pubmed:publicationType | Multicenter Study | lld:pubmed |
